Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Liquid Liver Biopsy: Detection of Circulating Epithelial Cells in Liver Disease

ABSTRACT: The Liquid Liver Biopsy: Detection of Circulating Epithelial Cells in Liver Disease

PROVIDER: PRJNA483004 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7607880_1.fastq.gz	Fastqsanger.gz
	SRR7607880_2.fastq.gz	Fastqsanger.gz
	SRR7607890_1.fastq.gz	Fastqsanger.gz
	SRR7607890_2.fastq.gz	Fastqsanger.gz
	SRR7607900_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 274

Similar Datasets

The Liquid Liver Biopsy: Detection of Circulating Epithelial Cells in Liver Disease

Project description:Using a microfluidic device, circulating epithelial cells (CECs) were enriched from peripheral blood from patients with chronlic liver disease and hepatocellular carcinoma. Select samples were further flow sorted for WBC subsets. CEC and WBC subsets transcriptomes were sequenced.

2019-07-24 | GSE117623 | GEO

Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

Project description:Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.

| 2269165 | ecrin-mdr-crc

Multi-parametric liquid biopsy approach

Project description:Multi-parametric liquid biopsy approach

| PRJEB39331 | ENA

DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy

Project description:Non-invasive detection of aberrant DNA methylation could provide invaluable biomarkers for earlier detection of triple negative breast cancer (TNBC) which could help clinicians for easier and more efficient treatment options. We evaluated genome-wide DNA methylation data derived from TNBC and normal breast tissues, peripheral blood of TNBC cases and controls, and reference samples of sorted blood and mammary cells. Differentially methylated regions (DMRs) between TNBC and normal breast tissues were stringently selected, verified, and externally validated. A machine learning algorithm was applied to select the top DMRs, which then were evaluated on plasma-derived circulating cell-free DNA (cfDNA) samples of TNBC patients and healthy controls. We identified 23 DMRs accounting for the methylation profile of blood cells and reference mammary cells and then selected six top DMRs for cfDNA analysis. We quantified un-/methylated copies of these DMRs by droplet digital PCR analysis in a plasma test set from TNBC patients and healthy controls and confirmed our findings obtained on tissues. Differential cfDNA methylation was confirmed in an independent validation set of plasma samples. A methylation score combining signatures of the top three DMRs overlapping with the SPAG6, LINC10606, and TBCD/ZNF750 genes had the best capability to discriminate TNBC patients from controls (AUC=0.74 in test set and AUC=0.77 in validation set). Our findings demonstrate the usefulness of cfDNA-based methylation signatures as non-invasive liquid biopsy markers for diagnosis of TNBC.

2022-11-23 | GSE207998 | GEO

Liquid biopsy and molecular genetics for monitoring and early detection of progression in melanoma patients

Project description:Liquid biopsy in melanoma

| PRJEB98726 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887892 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887893 | ENA

Pre-analytical factors affecting the establishment of a single tube assay for multi-parameter liquid biopsy detection in melanoma patients

Project description:NGS liquid biopsy sequencing of miRNAs in total plasma and EV-associated miRNAs

2020-03-10 | GSE143231 | GEO

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

Project description:Circulating Tumor Cells (CTCs) encompass multiple analytes, interrogated by sampling blood from patients with cancer. However, the clinical utility of tumor cell-based liquid biopsy has proven to be limited since CTCs are rare, and current technologies cannot process larger blood volumes required to isolate a sufficient number of tumor cells. We have described a high-throughput microfluidic prototype utilizing high-flow channels and amplification of cell sorting forces through magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from patients with metastatic cancer and achieving a median of 2,799 CTCs per patient. Isolation of many CTCs from individual patients enables characterization of their morphological and molecular heterogeneity, including cell and nuclear size and RNA expression. It also allows robust detection of gene copy number variation (CNV), a definitive cancer marker with potential diagnostic applications. High-volume microfluidic enrichment of CTCs constitutes a new dimension in liquid biopsies.

2024-08-27 | GSE255889 | GEO

DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy

Project description:DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy

| PRJNA857984 | ENA